AcelRx presents SAP301 data at annual ASPS meeting

AcelRx recently presented the analysis of the SAP301 trial at the ASPS annual meeting.
AcelRx recently presented the analysis of the SAP301 trial at the ASPS annual meeting. | shutterstock
AcelRx Pharmaceuticals Inc. recently presented the subgroup analysis from the SAP301 clinical study by board-certified plastic surgeon and AcelRx clinical investigator Dr. Shankar Lakshman at the American Society of Plastic Surgeons (ASPS) annual meeting.

The SAP301 Phase 3 clinical study compared ARX-04 to a placebo for the treatment of patients with moderate-to-severe acute pain after undergoing ambulatory abdominal surgery.

The presentation by Dr. Lakshman featured the activity of ARX-04 that was observed in 80 of the 161 patients who took part in the study who had abdominoplasty surgery in which ARX-04 showed a substantial statistical improvement in patients over placebo, which helped the study meet its primary goal in effectiveness.

The presentation took place on Sept. 24 and was titled “Phase 3 Results of Sublingual Sufentanil 30 mcg for the Management of Post-Operative Pain Following Abdominoplasty Surgery.”

The authors of the presentation are Dr. Lakshman of Pasadena Surgeons in Pasadena, California; Dr. Harold Minkowitz, Memorial Hermann Memorial City Medical Center in Houston, Texas; Dr. Timothy Melson, Helen Keller Hospital in Sheffield, Alabama; and Dr. David Leiman, Victory Medical Center in Houston, Texas.
Want to get notified whenever we write about AcelRx Pharmaceuticals, Inc. ?
Next time we write about AcelRx Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

AcelRx Pharmaceuticals, Inc. 351 Galveston Dr Redwood City, CA 94063